Circulating bioactive sclerostin levels in an Austrian population-based cohort

Summary Background Circulating serum sclerostin levels are supposed to give a good estimation of the levels of this negative regulator of bone mass within bone. Most studies evaluating total serum sclerostin found different levels in males compared to females and in older compared to younger subject...

Full description

Saved in:
Bibliographic Details
Published in:Wiener Klinische Wochenschrift 2022-01, Vol.134 (1-2), p.39-44
Main Authors: Kerschan-Schindl, Katharina, Föger-Samwald, Ursula, Gleiss, Andreas, Kudlacek, Stefan, Wallwitz, Jacqueline, Pietschmann, Peter
Format: Article
Language:English
Subjects:
Aged
Austria
Biomarkers
Bone Density
Bone Morphogenetic Proteins
Cross-Sectional Studies
Endocrinology
Female
Gastroenterology
Genetic Markers
Humans
Internal Medicine
Male
Medicine
Medicine & Public Health
Original
Original Article
Pneumology/Respiratory System
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Circulating serum sclerostin levels are supposed to give a good estimation of the levels of this negative regulator of bone mass within bone. Most studies evaluating total serum sclerostin found different levels in males compared to females and in older compared to younger subjects. Besides an ELISA detecting total sclerostin an ELISA determining bioactive sclerostin has been developed. The aim of this study was to investigate serum levels of bioactive sclerostin in an Austrian population-based cohort. Methods We conducted a cross-sectional observational study in 235 healthy subjects. Using the bioactive ELISA assay (Biomedica) bioactive sclerostin levels were evaluated. Results Serum levels of bioactive sclerostin were higher in men than in women (24%). The levels correlated positively with age (r = 0.47). A positive correlation could also be detected with body mass index and bone mineral density. Conclusion Using the ELISA detecting bioactive sclerostin our results are consistent with data in the literature obtained by different sclerostin assays. The determination of sclerostin concentrations in peripheral blood thus appears to be a robust parameter of bone metabolism.
ISSN:0043-5325
1613-7671
DOI:10.1007/s00508-021-01815-0